BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38022847)

  • 1. Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review).
    Alhejaily AG; Alhuzim O; Alwelaie Y
    Mol Clin Oncol; 2023 Dec; 19(6):99. PubMed ID: 38022847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.
    Gómez Sáez JM; Jiménez-Fonseca P; Santamaría Sandi J; Capdevila Castillón J; Navarro González E; Zafón Llopis C; Ramón Y Cajal Asensio T; Riesco Eizaguirre G; Grande Pulido E; Galofré Ferrater JC
    Endocrinol Nutr; 2015 Mar; 62(3):e15-22. PubMed ID: 25583658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
    Smith N; Nucera C
    J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular therapeutics for anaplastic thyroid cancer.
    Pozdeyev N; Rose MM; Bowles DW; Schweppe RE
    Semin Cancer Biol; 2020 Apr; 61():23-29. PubMed ID: 31991166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.
    Sugitani I; Miyauchi A; Sugino K; Okamoto T; Yoshida A; Suzuki S
    World J Surg; 2012 Jun; 36(6):1247-54. PubMed ID: 22311136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer.
    Smallridge RC; Ain KB; Asa SL; Bible KC; Brierley JD; Burman KD; Kebebew E; Lee NY; Nikiforov YE; Rosenthal MS; Shah MH; Shaha AR; Tuttle RM;
    Thyroid; 2012 Nov; 22(11):1104-39. PubMed ID: 23130564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer.
    Ljubas J; Ovesen T; Rusan M
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31277524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision Medicine Approach to Anaplastic Thyroid Cancer: Advances in Targeted Drug Therapy Based on Specific Signaling Pathways.
    Samimi H; Fallah P; Naderi Sohi A; Tavakoli R; Naderi M; Soleimani M; Larijani B; Haghpanah V
    Acta Med Iran; 2017 Mar; 55(3):200-208. PubMed ID: 28282720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
    Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
    Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [No Abstract]   [Full Text] [Related]  

  • 11. Evolution of anaplastic thyroid cancer management: perspectives in the era of precision oncology.
    Agosto Salgado S
    Ther Adv Endocrinol Metab; 2021; 12():20420188211054692. PubMed ID: 34733469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer.
    Saini S; Maker AV; Burman KD; Prabhakar BS
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188262. PubMed ID: 30605717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic Thyroid Cancer: New Horizons and Challenges.
    Maniakas A; Zafereo M; Cabanillas ME
    Endocrinol Metab Clin North Am; 2022 Jun; 51(2):391-401. PubMed ID: 35662448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.
    Agarwal R; Wang J; Wilson K; Barrett W; Morris JC
    J Natl Compr Canc Netw; 2016 Oct; 14(10):1203-1207. PubMed ID: 27697975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches.
    Are C; Shaha AR
    Ann Surg Oncol; 2006 Apr; 13(4):453-64. PubMed ID: 16474910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review.
    Salehian B; Liem SY; Mojazi Amiri H; Maghami E
    Int J Endocrinol Metab; 2019 Jan; 17(1):e67759. PubMed ID: 30881466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review.
    Guerra A; Di Crescenzo V; Garzi A; Cinelli M; Carlomagno C; Tonacchera M; Zeppa P; Vitale M
    BMC Surg; 2013; 13 Suppl 2(Suppl 2):S44. PubMed ID: 24267151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of anaplastic thyroid cancer.
    Keutgen XM; Sadowski SM; Kebebew E
    Gland Surg; 2015 Feb; 4(1):44-51. PubMed ID: 25713779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress of genome study for anaplastic thyroid cancer.
    Lee J; Hwang JA; Lee EK
    Genomics Inform; 2013 Jun; 11(2):68-75. PubMed ID: 23843772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.